FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis
PR Newswire
INDIANAPOLIS, June 9, 2026
View original content to download multimedia:https://www.prnewswire.com/news-releases/fda-approves-lillys-ebglyss-lebrikizumab-lbkz-for-one-maintenance-dose-every-eight-weeks-in-patients-with-moderate-to-severe-atopic-dermatitis-302795876.htmlSOURCE Eli Lilly and Company
The articles, information, and content displayed on this webpage may
